Antibodies
Gemcitabine
- 貨號 Cat. No.
- S1714
- 規格 Size
- 10mM/1mLã€50mg
- 品牌 Brand
- Selleckchem
Description
Gemcitabine
Gemcitabine belongs to the group of medicines called antimetabolites.Phase 3.
| Size | Price | Stock | Quantity | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
Gemcitabine(Gemzar) belongs to the group of medicines called antimetabolites. It is used alone or in combination with other medicines to treat cancer of the breast, ovary, pancreas, and lung. Gemcitabine interferes with the growth of cancer cells, which are eventually destroyed.[1, 2]
Clinical Trial Information( data from http://clinicaltrials.gov)
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01956812 | Not yet recruiting | Metastatic Pancreatic Cancer|Pancreatic Cancer | Immunomedics, Inc. | 2013-12 | Phase 3 |
| NCT01964430 | Not yet recruiting | Pancreatic Neoplasms|Digestive System Neoplasms|Neoplasms by Site|Neoplasms|Endocrine Gland Neoplasms|Pancreatic Diseases|Digestive System Diseases|Endocrine System Diseases|Gemcitabine|Antimetabolite | Celgene Corporation | 2014-01 | Phase 3 |
| NCT01830322 | Withdrawn | Metastatic Pancreatic Adenocarcinoma | Cornerstone Pharmaceuticals, Inc. | 2014-01 | Phase 2 |
| NCT02016417 | Not yet recruiting | Nasopharyngeal Carcinoma | Cancer Hospital of Guangxi Medical University | 2014-01 | Phase 2 |
| NCT01852890 | Not yet recruiting | Pancreatic Neoplasms | University of Iowa|Joseph J. Cullen | 2014-02 | Phase 1 |
Chemical Information
| Molecular Weight (MW) | 263.2 |
|---|---|
| Formula | C9H11F2N3O4 |
| CAS No. | 95058-81-4 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | Gemzar |
| Solubility (25°C) * | In vitro | DMSO | 15 mg/mL (56 mM) |
|---|---|---|---|
| Water | <1 mg/mL (<1 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| In vivo | 30% PEG400/0.5% Tween80/5% propylene glycol, | 30 mg/mL | |
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name |
|---|
Preparing Stock Solutions
| Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
|---|---|---|---|---|
| Mass(mg) | 0.2632 | 2.632 | 5.264 | 7.896 |
Customer Reviews (1)
 Click to enlarge | Rating | |
| Source | Dr. Helen Sadik of Johns Hopkins University. Gemcitabine purchased from Selleck | |
| Method | MTT assays | |
| Cell Lines | MCF7 cells, MCF10A cells | |
| Concentrations | 0.01-100 μM | |
| Incubation Time | 48 h | |
| Results | Gemcitabine potently inhibited the survival of MCF10A cells in a dose-dependent manner. The highest level of inhibition was observed with Gemcitabine HCl in concentration of 0.01 μM in MCF7 cells |
Product Citations (3)
Anticancer compound ABT-263 accelerates apoptosis in virus-infected cells and imbalances cytokine production and lowers survival rates of infected mice. [Kakkola L, et al. Cell Death Dis 2013;4:e742]
Age-Enhanced Endoplasmic Reticulum Stress Contributes to Increased Atg9A Inhibition of STING-Mediated IFN-β Production during Streptococcus Pneumoniae Infection. [Mitzel DN, et al. J Immunol 2014;10.4049/jimmunol.1303090]
Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. [Booth L , et al. Mol Pharmacol 2013;85(3):408-19]
